Modular Medical, Inc. is an emerging medical technology company primarily focused on the creation, refinement, and market introduction of insulin pumps. The ...
Modular Medical, Inc. (MODD) is a healthcare/medical-devices company headquartered in San Diego, California. The company’s core mission is to make insulin pump therapy easier to adopt and more broadly accessible for individuals living with diabetes by reducing complexity and lowering the practical barriers to using pump-based insulin delivery systems.
Business focus and product direction center on the MODD1 insulin pump platform. The company positions its technology as a way to remove “complicated technology,” enabling a smoother transition for users who may be coming from manual injections. In this context, Modular Medical’s product strategy appears oriented toward usability and adoption: simplifying the user experience and streamlining the path from conventional diabetes management into automated or semi-automated insulin delivery.
From a services/market perspective, as a medical-device developer it typically partners with clinical and regulatory stakeholders and progresses through design refinement, market introduction, and human-use milestones. The materials provided reference the company’s announcement of first human use of MODD1 and describe MODD as a next-generation insulin pump intended for launch.
Cost and affordability are recurring themes. The company states an intent to make higher-quality pump care affordable and easy to use. While specific bill-of-materials (BOM), unit cost targets, or manufacturing economics are not detailed in the provided information, the business rationale is consistent with reducing complexity and effort in the overall system so that the resulting therapy may be offered at a lower effective burden to patients and/or payers.
Financially, the provided dataset indicates the company is still in an investment/transition phase, with negative profitability metrics in trailing-twelve-month measures. That profile is common for development-stage medical technology firms that incur R&D and commercialization costs before achieving sustained revenue and margin expansion.
Key people highlighted in the provided information include CEO James E. Besser (with additional context referencing founder Paul DiPerna as a medical-device professional). Looking forward, the company’s “wishes” and objectives, based on its stated mission, are to liberate and empower the diabetes community through widely usable diabetes technology and to expand access to pump therapy through simplification and affordability.
